1. Generics Bulletin
  2. >>Business
  3. >>Strategy

Lannett’s Insulin Aspart Biosimilar Takes ‘Major Step’ Forward

Lannett’s Insulin Aspart On Track For Key Development Milestones After Positive Animal Study Results

 
• By Rosalind Rei

Lannett and HEC’s insulin aspart biosimilar has performed well on an animal study in a boost to its strategic pipeline. Meanwhile, their insulin glargine faces delays.  

Laboratory worker writes on clipboard, with test-tube rack in the foreground
Lannett's Insulin Aspart Is A Major Pipeline Asset For the US Firm • Source: Shutterstock

New animal study results show that Lannett’s biosimilar insulin aspart candidate is “highly comparable” to Novo Nordisk’s US NovoLog, its reference biologic.

The pharmacokinetic study involved dosing animals with equal quantities of the

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Strategy

More from Business